Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R J Motzer

Showing results (61-70 of 155) with videos related to

Pageof 16
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1994
Advanced seminoma: treatment results, survival, and prognostic factors in 142 patientsP J Mencel, R J Motzer, M Mazumdar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1995
Molecular and cytogenetic studies in the diagnosis of patients with poorly differentiated carcinomas of unknown primary siteR J Motzer, E Rodriguez, V E Reuter, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1997
Ifosfamide- and cisplatin-containing chemotherapy as first-line salvage therapy in germ cell tumors: response and survivalJ A McCaffrey, M Mazumdar, D F Bajorin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 20, 1998
Metastatic germ cell tumors: modeling for response to chemotherapyD F Bajorin, M Mazumdar, M Meyers, et al.
Journal of the National Cancer Institute|March 2, 1994
Clinical relevance of the i(12p) marker chromosome in germ cell tumorsG J Bosl, D H Ilson, E Rodriguez, et al.
Investigational New Drugs|August 25, 2000
Phase II trial of pyrazoloacridine in patients with cisplatin-refractory germ cell tumorsJ Vuky, J McCaffrey, M Ginsberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 7, 2001
Phase I trial of 40-kd branched pegylated interferon alfa-2a for patients with advanced renal cell carcinomaR J Motzer, A Rakhit, M Ginsberg, et al.
Cancer|May 15, 1994
Serum tumor marker decline is an early predictor of treatment outcome in germ cell tumor patients treated with cisplatin and ifosfamide salvage chemotherapyB A Murphy, R J Motzer, M Mazumdar, et al.
European Journal of Cancer (Oxford, England : 1990)|September 21, 2013
Sunitinib objective response in metastatic renal cell carcinoma: analysis of 1059 patients treated on clinical trialsA M Molina, X Lin, B Korytowsky, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2000
Paclitaxel, ifosfamide, and cisplatin second-line therapy for patients with relapsed testicular germ cell cancerR J Motzer, J Sheinfeld, M Mazumdar, et al.
Pageof 16

Showing results (61-70 of 155) with videos related to

Sort By:
Pageof 16
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1994
Advanced seminoma: treatment results, survival, and prognostic factors in 142 patientsP J Mencel, R J Motzer, M Mazumdar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1995
Molecular and cytogenetic studies in the diagnosis of patients with poorly differentiated carcinomas of unknown primary siteR J Motzer, E Rodriguez, V E Reuter, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1997
Ifosfamide- and cisplatin-containing chemotherapy as first-line salvage therapy in germ cell tumors: response and survivalJ A McCaffrey, M Mazumdar, D F Bajorin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 20, 1998
Metastatic germ cell tumors: modeling for response to chemotherapyD F Bajorin, M Mazumdar, M Meyers, et al.
Journal of the National Cancer Institute|March 2, 1994
Clinical relevance of the i(12p) marker chromosome in germ cell tumorsG J Bosl, D H Ilson, E Rodriguez, et al.
Investigational New Drugs|August 25, 2000
Phase II trial of pyrazoloacridine in patients with cisplatin-refractory germ cell tumorsJ Vuky, J McCaffrey, M Ginsberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 7, 2001
Phase I trial of 40-kd branched pegylated interferon alfa-2a for patients with advanced renal cell carcinomaR J Motzer, A Rakhit, M Ginsberg, et al.
Cancer|May 15, 1994
Serum tumor marker decline is an early predictor of treatment outcome in germ cell tumor patients treated with cisplatin and ifosfamide salvage chemotherapyB A Murphy, R J Motzer, M Mazumdar, et al.
European Journal of Cancer (Oxford, England : 1990)|September 21, 2013
Sunitinib objective response in metastatic renal cell carcinoma: analysis of 1059 patients treated on clinical trialsA M Molina, X Lin, B Korytowsky, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2000
Paclitaxel, ifosfamide, and cisplatin second-line therapy for patients with relapsed testicular germ cell cancerR J Motzer, J Sheinfeld, M Mazumdar, et al.
Pageof 16